Intellia Therapeutics, Inc.
NTLA
$13.39
-$0.09-0.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.92% | 33.52% | 14.99% | -13.37% | 59.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.92% | 33.52% | 14.99% | -13.37% | 59.55% |
| Cost of Revenue | -18.90% | -14.61% | -8.55% | -7.14% | -3.21% |
| Gross Profit | 24.60% | 19.96% | 11.33% | 6.31% | 8.92% |
| SG&A Expenses | -2.28% | 12.19% | 23.72% | 40.63% | 46.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.10% | -7.67% | -0.90% | 2.93% | 7.36% |
| Operating Income | 17.46% | 10.97% | 2.29% | -4.59% | -3.68% |
| Income Before Tax | 20.49% | 14.64% | 5.62% | -8.32% | -7.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.49% | 14.64% | 5.62% | -8.32% | -7.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.49% | 14.64% | 5.62% | -8.32% | -7.86% |
| EBIT | 17.46% | 10.97% | 2.29% | -4.59% | -3.68% |
| EBITDA | 17.70% | 11.14% | 2.39% | -4.51% | -3.49% |
| EPS Basic | 27.11% | 21.66% | 14.42% | 2.57% | 3.09% |
| Normalized Basic EPS | 22.30% | 17.16% | 11.24% | 6.89% | 9.24% |
| EPS Diluted | 27.11% | 21.66% | 14.42% | 2.57% | 3.09% |
| Normalized Diluted EPS | 22.30% | 17.16% | 11.24% | 6.89% | 9.24% |
| Average Basic Shares Outstanding | 9.61% | 9.20% | 10.36% | 11.17% | 11.34% |
| Average Diluted Shares Outstanding | 9.61% | 9.20% | 10.36% | 11.17% | 11.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |